Edwards Lifesciences Sees Unusually Large Options Volume (EW)

Edwards Lifesciences Corp (NYSE:EW) saw some unusual options trading activity on Monday. Stock investors purchased 8,976 call options on the company. This is an increase of 1,311% compared to the average volume of 636 call options.

In other Edwards Lifesciences news, VP Larry L. Wood sold 6,716 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $148.15, for a total value of $994,975.40. Following the transaction, the vice president now directly owns 122,366 shares of the company’s stock, valued at approximately $18,128,522.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the stock in a transaction dated Friday, December 21st. The shares were sold at an average price of $146.03, for a total transaction of $4,789,784.00. Following the completion of the transaction, the chief executive officer now directly owns 75,926 shares in the company, valued at $11,087,473.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 169,668 shares of company stock worth $27,195,828. 1.84% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Executive Wealth Management LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $25,000. Sontag Advisory LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Lindbrook Capital LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $27,000. Capital Financial Planning LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 83.09% of the company’s stock.

Shares of NYSE:EW opened at $190.89 on Tuesday. Edwards Lifesciences has a 12-month low of $123.00 and a 12-month high of $197.86. The company has a market cap of $37.35 billion, a price-to-earnings ratio of 40.61, a price-to-earnings-growth ratio of 2.32 and a beta of 0.90. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.17. The business had revenue of $977.70 million for the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same quarter last year, the business posted $0.94 EPS. Equities analysts expect that Edwards Lifesciences will post 5.21 earnings per share for the current fiscal year.

Several research analysts have weighed in on the stock. Canaccord Genuity reissued a “buy” rating and issued a $215.00 price target (up from $190.00) on shares of Edwards Lifesciences in a report on Monday. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a report on Monday. Royal Bank of Canada increased their price target on shares of Edwards Lifesciences to $175.00 and gave the company an “outperform” rating in a report on Thursday, December 6th. UBS Group increased their price target on shares of Edwards Lifesciences from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Tuesday, March 12th. Finally, Stifel Nicolaus reissued a “positive” rating on shares of Edwards Lifesciences in a report on Thursday, December 6th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $176.00.

COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2019/03/19/edwards-lifesciences-sees-unusually-large-options-volume-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: What is a Futures Contract?

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.